The A2 Milk Company: Lack of transparency in key channel
About the author:
- Author name:
- By Belinda Moore
- Job title:
- Senior Analyst
- Date posted:
- 21 December 2020, 9:00 AM
- Sectors Covered:
- Agriculture, Food & Beverage, Travel
- While 2Q21 infant formula sales improved on the 1Q21, they have been below
budget and consequently, A2M has materially downgraded its FY21 guidance.
While guidance always looked too optimistic, the extent of the downgrade is
disappointing and highlights how important the daigou is to A2M’s growth and the
lack of transparency in this channel.
- We have made material revisions to our forecasts.
- While uncertainty remains, A2M’s share price may remain subdued, however we
continue to believe the company is well placed over the medium to longer term
once channels normalise and maintain an Add rating with a new price target (login to view).
Downgrades both 1H21 and FY21 guidance
Only one month since guidance was reiterated, A2M has downgraded its 1H21 revenue
guidance by 8-14% (NZ$55-105m). While 2Q21 revenue will be higher than the 1Q21,
December trading has been materially weaker than expected.
The 1H21 EBITDA margin
is now expected to be 27% (~31% before), implying EBITDA of NZ$180.9m (-32% on
1H20) which was 22% below our previous forecast. Additionally, FY21 revenue guidance
has been downgraded by 18-22% and with lower margin expectations, EBITDA has been
revised by 24-35%.
A2M now forecasts a weak 2H21 (revenue down 5-21% on 2H20)
compared to previous expectations of solid double-digit growth.
Rate of recovery slower than anticipated
A2M continues to be impacted by pantry destocking following its strong 3Q20 result and
lower than anticipated sales to the Australian retail daigou channel due to reduced tourism
from China and international students.
Additionally, sales to the corporate daigou channel,
have been slower than expected (reseller margins have been under pressure).
Furthermore, sales through the CBEC channel have weakened since China’s Singles Day
driven by the disruption to the daigou channel, which typically helps to stimulate consumer
A strengthening NZDUSD has been a further earnings headwind. A2M does not
believe China/Australia trade tensions have impacted its business and instead, the issues
facing the company are more a consequence of COVID-19.
We revise our forecasts
Given A2M’s weaker-than-expected guidance, we have reduced our FY21/22/23 NPAT
forecasts by 27.8%/28.4%/28.9% respectively. Our new forecast is at the lower end of
A2M’s sales guidance.
In FY21, we forecast NPAT to fall by 30%. We forecast solid
earnings growth from FY22 onwards driven by a recovery in the corporate and retail
daigou as COVID-19 restrictions ease and ongoing growth in the China and North
American businesses from increased distribution and higher sales velocities.
We note our
FY22-23 NPAT forecasts are well below A2M’s FY20 result. Over the medium term, A2M
continues to target an EBITDA margin in the order of 30% (was 31.9% in FY20A). Our
forecasts are now more conservative than this assumption with an EBITDA margin of
27.3% and 27.6% in FY23 and FY24.
Investment view – Add and updated price target
Given the extent/timing of the FY21 earnings downgrades, it will take time for A2M to
rebuild investor confidence. On a positive note, A2M’s China brand metrics remain strong,
with MBS market share rising to 2.3% in October (vs. 2.0% in Jun-20), 1H21 sales are
expected to rise >40% and brand awareness and loyalty is increasing.
Given the size of
the MBS market, we expect A2M to deliver strong growth in this channel over coming
years as further share is gained. Its balance sheet also remains in a strong net cash
position (+NZ$1.0bn) and it was revealed that the Board is considering a share buy-back
given severe share price weakness and its belief that the company is well positioned over
the medium to longer term.
As we have seen with other infant formula companies, the
weakness could be a catalyst for corporate activity. Ex cash, A2M is now trading on an
FY22 PE of 22x. The key risk is if trading conditions don’t improve and/or A2M gets caught
up in geopolitical tensions with China.
Find out more
Download full research note
If you would like access or more information, please contact your adviser or nearest Morgans office.
Request a call
Find local branch
Need access to our research?
You are also welcome to start a two-week trial of our online platform, which provides access to detailed market analysis and insights, provided by our award-winning research team.
Create trial account
Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.